Skip to main navigation

News
Alerts
Careers
Contact

About
Pipeline
Rezafungin
Cloudbreak
Publications
Investors
Secondary Investor Relations

Press enter to begin your search

Home
About
Drug Candidates
- Pipeline
- CD101 IV
- CD101 Topical
- C001
- Publications
Cloudbreak
Opportunity
Investors
Secondary Investor Relations
Contact

Event Calendar

Event Calendar

UPCOMING EVENTS

More events are coming soon.

NAVIGATION

Overview
Financials
- SEC Filings
Stock Information
Corporate Governance
News & Events
Analyst Coverage
Shareholder Services

Tool Kit

	Print Page
	RSS Feeds
	E-mail Alerts

Get Important News and Updates by Email Subscribe

About Cidara

Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives and immunotherapies that have the potential to transform the standard of care and save or improve patients' lives.
Learn more >>

Recent News

Cidara Therapeutics Announces Rezafungin Presentations at the 2019 European Society for Blood and Marrow Transplantation Meeting

March 7, 2019

Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results

February 28, 2019

Cidara Therapeutics Announces Rezafungin Presentations at the 2019 Transplantation and Cellular Therapy (TCT) Meeting

February 5, 2019

Navigation

Secondary Investor Relations

Overview
Presentations
Financials
Stock Information
Corporate Governance
News & Events
Analyst Coverage
Shareholder Services

Contact Us

Cidara Therapeutics, Inc.
6310 Nancy Ridge Drive, Suite 101
San Diego, CA 92121
Tel: (858) 752-6170
Email: info@cidara.com

© 2019 Cidara Therapeutics, Inc. | Terms of Use | Privacy Policy

Quick Links

Secondary Investor Relations

Overview
Presentations
Financials
Stock Information
Corporate Governance
News & Events
Analyst Coverage
Shareholder Services

Tweets by @CidaraThera